A share price of Tenaya Therapeutics Inc [TNYA] is currently trading at $0.51, up 3.55%. An important factor to consider is whether the stock is rising or falling in short-term value. The TNYA shares have gain 21.74% over the last week, with a monthly amount drifted -30.49%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on November 30, 2023, and set its price target to $7. On June 15, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock.
Tenaya Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.39 and $4.96. Tenaya Therapeutics Inc [NASDAQ: TNYA] shares were valued at $0.51 at the most recent close of the market.
Analyzing the TNYA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.93, Equity is -0.89 and Total Capital is -1.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.4875 points at the first support level, and at 0.4676 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.5176, and for the 2nd resistance point, it is at 0.5278.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Tenaya Therapeutics Inc [NASDAQ:TNYA] is 4.22. On the other hand, the Quick Ratio is 4.22, and the Cash Ratio is 0.27.
Transactions by insiders
Recent insider trading involved Higa Tomohiro, SVP, Finance, that happened on Mar 10 ’25 when 2482.0 shares were sold. Chief Medical Officer, Tingley Whittemore completed a deal on Mar 10 ’25 to sell 7398.0 shares. Meanwhile, Chief Executive Officer Ali Faraz sold 9741.0 shares on Mar 10 ’25.
